Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

Gilead Sciences on Thursday reported flat second-quarter earnings on slightly higher revenue and raised its full-year ...

Gilead Sciences, Inc. (NASDAQ:GILD) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Gilead Sciences, Inc.

Gilead Sciences delivered a better-than-expected second quarter, propelled by the strong performance of its HIV portfolio and ...

Gilead Sciences, Inc.'s HIV dominance with Biktarvy & Yeztugo boosts revenue potential. Click for more about GILD and its ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 1 ...

Despite decades of medical progress, HIV continues to devastate Black communities. The statistics are sobering. The ...

With Black women and straight men increasingly at risk, Gilead’s Yeztugo may finally offer a discreet, stigma-free way to stop the spread of HIV before the system fails them.

The U.S. Preventive Services Task Force makes recommendations for preventive services—including Gilead’s twice-yearly HIV ...

The U.S. alone sees 700 new cases and 100 HIV-related deaths each week, Gilead CEO Daniel O'Day said in an interview ahead of the approval.